As it awaits status of Moderna vaccine, Swedish CDMO receives tender
Private equity firm EQT AB has made an offer to acquire Recipharm AB, a contract development and manufacturing organization (CDMO), for $2.1 billion, EQT announced. The offer is expected to be made public on or around Dec. 17.
As Bloomberg reported, Sweden-based EQT has already secured ownership of about 25.7% of the shares and 74.3% of the votes in Recipharm via its chairman, Lars Backsell, and Thomas Eldered, its CEO.
The firm will be offering shareholders $26.24 in cash per share, the report stated.
Other reports noted that Recipharm recently signed a preliminary deal with Moderna Inc to fill and seal the packaging for the biotech's mRNA Covid-19 vaccine.
Recipharm signed a letter of intent with Moderna to help "formulate, fill and finish" its Covid-19 vaccine, as an FDA advisory board prepares to meet on Thursday to discuss Moderna's request for emergency use authorization (EUA).
Multi-Indication Drug Branding in Today’s Pharmaceutical Industry
July 2nd 2025As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.